Key result
Plasma kallikrein activity is positively associated with eGFR (β = 0.24) and decreases with more advanced stages of diabetic nephropathy in individuals with type 1 diabetes.
Why the study?
The plasma kallikrein-kinin system is involved in vascular control and thrombin formation, but the impact of plasma kallikreins on diabetic nephropathy remains unknown.
Cross-Sectional (n=295)
Yes
Decreased plasma kallikrein activity and genetic variants affecting its levels are associated with reduced kidney function in type 1 diabetes, suggesting a potential protective role for plasma kallikrein in diabetic nephropathy.
Lower plasma kallikrein activity was associated with reduced eGFR in type 1 diabetes; hypothesis-generating for a protective role pending prospective validation.
AIMS/HYPOTHESIS: Plasma kallikrein is the central mediator of the plasma kallikrein-kinin system, which is involved both in vascular control and thrombin formation cascades. The plasma kallikrein-kinin system has also been considered protective in pathological conditions, but the impact of plasma kallikreins on diabetic nephropathy remains unknown. The objective of this cross-sectional study was to explore the association of plasma kallikrein with diabetic nephropathy. METHODS: We measured plasma kallikrein activity in 295 individuals with type 1 diabetes at various stages of diabetic nephropathy, and we tested the genetic association between the plasma kallikrein-kinin system and kidney function in 4400 individuals with type 1 diabetes. RESULTS: Plasma kallikrein activity was associated with diabetes duration (p < 0.001) and eGFR (p < 0.001), and plasma kallikrein activity was lower with more advanced diabetic nephropathy, being lowest in individuals on dialysis. The minor alleles of the KNG1 rs5030062 and rs710446 variants, which have previously been associated with increased plasma pre-kallikrein and/or factor XI (FXI) protein levels, were associated with higher eGFR (rs5030062 β = 0.03, p = 0.01; rs710446 β = 0.03, p = 0.005) in the FinnDiane cohort of 4400 individuals with type 1 diabetes. CONCLUSIONS/INTERPRETATION: Plasma kallikrein activity and genetic variants known to increase the plasma kallikrein level are associated with higher eGFR in individuals with type 1 diabetes, suggesting that plasma kallikrein might have a protective effect in diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Härma et al. (2020) conducted a cross-sectional in Type 1 diabetes and diabetic nephropathy (n=295). Plasma kallikrein activity vs. Unexposed/reference group (varying levels of activity) was evaluated on Estimated glomerular filtration rate (eGFR) (β = 0.24, 95% CI 0.14-0.34, p=<0.001). Plasma kallikrein activity is positively associated with eGFR (β = 0.24) and decreases with more advanced stages of diabetic nephropathy in individuals with type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: